Neusentis

Neusentis was a specialized research and development unit of Pfizer, primarily based in Cambridge, UK, focused on discovering and developing treatments for pain and sensory disorders. Launched in 2011, the unit integrated Pfizer's existing pain research expertise with the ion channel technology acquired from Icagen. The organization focused heavily on ion channel modulators, particularly targeting Nav1.7 for the treatment of chronic and neuropathic pain. In late 2015, Pfizer announced the closure of the Neusentis facility as part of a strategic shift, though some programs were transitioned back into Pfizer's global R&D portfolio. The unit was notable for its biotech-style autonomy and its strategic location within the Cambridge life sciences cluster.